A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs HTD 1801 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Proof of concept; Therapeutic Use
- Sponsors HighTide Biopharma
- 12 Feb 2018 Status changed from not yet recruiting to recruiting.
- 03 Jan 2018 Planned initiation date changed from 7 Dec 2017 to 8 Jan 2018.
- 10 Nov 2017 New trial record